A zinc finger nuclease gene editing technology is to be used to develop ex vivo cell therapies for cancer, under a new research collaboration between the Gilead Sciences company Kite and Sangamo Therapeutics Inc. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
